Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Arnd Nusch"'
Autor:
Patrick Neven, Xavier Pivot, Antonia Ridolfi, Brad Lanoue, J. Thaddeus Beck, Guy Jerusalem, Arnd Nusch, Francisco J. Esteva, Giulia Bianchi, David Chandiwana, Miguel Martin, Karen Rodriguez Lorenc, Peter A. Fasching, Arlene Chan, Yingbo Wang, Michele De Laurentiis
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 54, Iss, Pp 148-154 (2020)
Breast, Vol 54, Iss, Pp 148-154 (2020)
Purpose In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and o
Autor:
JT Beck, Arunava Chakravartty, U. Deore, Craig Wang, Y. Ji, Juan Pablo Zarate, K. Petrakova, G. Valeria Bianchi, Arnd Nusch, Patrick Neven, S-A. Im, S Chia, Tanya Taran, Gabe S. Sonke, Miguel Martin, Guy Jerusalem, Peter A. Fasching, Dennis J. Slamon, M. De Laurentiis, L. de la Cruz-Merino
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(8)
BACKGROUND: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced bre
Autor:
Gabe S. Sonke, K Rodriguez Lorenc, Stephen Chia, Nadia Solovieff, Faye Su, JT Beck, L. De la Cruz-Merino, Guy Jerusalem, Patrick Neven, G Val Bianchi, K. Petrakova, M. Miller, S-A Lm, Arnd Nusch
Publikováno v:
Cancer Research. 79:PD2-05
Background: In the Phase III MONALEESA-3 (NCT02422615) study, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + fulvestrant (FUL) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + FUL in postmenopausal women with horm
Autor:
JT Beck, G. Jerusalem, Patrick Neven, Brad Lanoue, Peter A. Fasching, M. Martin Jimenez, Thomas E. Delea, S-A. Im, Arnd Nusch, A. Lonshteyn, M. De Laurentiis, A. Chan, David Chandiwana
Publikováno v:
Annals of Oncology. 31:S66
Autor:
Anne Favret, Kimberly L. Blackwell, Samit Hirawat, Erik Jakobsen, Carlos L. Arteaga, Emilio Alba, Shani Paluch-Shimon, Pierfranco Conte, Salomon M. Stemmer, Mario Campone, A. Chan, Lowell L. Hart, Thomas Bachelot, Fengjuan Xuan, David Cameron, Sunil Verma, Sibel Blau, Denise A. Yardley, Gabe S. Sonke, Farida Souami, Gabriel N. Hortobagyi, Katarína Petráková, Norbert Marschner, Wolfgang Janni, Fabrice Andre, Cristian Villanueva, Arnd Nusch, Eric P. Winer, Olga Burdaeva, Yoon Sim Yap, Joyce O'Shaughnessy, C. Germa, Michelle Miller, Erik Wist, Eva-Maria Grischke, Ling-Ming Tseng, Howard A. Burris
Publikováno v:
Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y-S, Sonke, G S, Paluch-Shimon, S, Campone, M, Blackwell, K L, André, F, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Petrakova, K, Hart, L L, Villanueva, C, Chan, A, Jakobsen, E, Nusch, A, Burdaeva, O, Grischke, E-M, Alba, E, Wist, E, Marschner, N, Favret, A M, Yardley, D, Bachelot, T, Tseng, L-M, Blau, S, Xuan, F, Souami, F, Miller, M, Germa, C, Hirawat, S & O’Shaughnessy, J 2016, ' Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer ', New England Journal of Medicine, vol. 375, no. 18, pp. 1738-1748 . https://doi.org/10.1056/NEJMoa1609709
BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8dab1e35ee3ea5009a3a02e3727218
https://hdl.handle.net/10668/10515
https://hdl.handle.net/10668/10515
Autor:
Cristian Villanueva, Gabe S. Sonke, Anne Favret, Yoon Sim Yap, Arnd Nusch, Carlos L. Arteaga, Katarína Petráková, Hege O. Ohnstad, Gabriel N. Hortobagyi, Shani Paluch-Shimon, M. Miller, Arlene Chan, Salomon M. Stemmer, Fei Su, Lowell L. Hart, Wei He, Norbert Marschner
Publikováno v:
Journal of Clinical Oncology. 36:1022-1022
1022Background: In MONALEESA-2, first-line RIB + LET improved investigator-assessed progression-free survival (PFS; primary endpoint) vs placebo (PBO) + LET in postmenopausal pts with HR+, HER2– AB...
Autor:
Thomas Bachelot, Kimberly L. Blackwell, Joseph Kattan, Emilio Alba, Bhuvaneswari Ramaswamy, Joseph A. Sparano, Fadi El Karak, Miguel Gil, Lowell L. Hart, M. Miller, Hugues Bourgeois, Howard A. Burris, Arlene Chan, Santosh Sutradhar, Donald A. Richards, Arnd Nusch, Wolfgang Janni, Denise A. Yardley, Olga Burdaeva, Pierfranco Conte
Publikováno v:
Journal of Clinical Oncology. 35:1047-1047
1047 Background: In the randomized, phase III MONALEESA-2 study (NCT01958021), first-line therapy with ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor; 600 mg/day; 3-weeks-on/1-week-off) + letrozole (LET; 2.5 mg/day) in postmenopausal women wi